Light Horse has developed a proprietary platform that uncovers novel functional sites in disease-critical targets. The company integrated distinct approaches to build this precision genetic editing-based platform that interrogates proteins in their native environment. The company’s technology turns conventional drug discovery on its head by first identifying novel functional domains and then screening for chemistry.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze